What is the SaiyanMed focus on in-vitro evaluation?
The focus of SaiyanMed's in-vitro evaluation is to rigorously verify the purity, identity, and concentration of research-grade peptides through standardized, non-biological testing protocols, ensuring that every batch meets the highest analytical standards for laboratory use only. In-vitro evaluation, which means "in glass" or within a controlled laboratory environment, is the cornerstone of SaiyanMed's quality assurance process. This approach allows researchers to trust that the peptides they receive are free from contaminants, correctly sequenced, and accurately dosed, which is critical for reproducible scientific experiments. Unlike in-vivo studies that involve living organisms, SaiyanMed's in-vitro evaluation relies on advanced analytical chemistry techniques to characterize the peptide raw materials and lyophilized products without introducing biological variables. This focus is not just a marketing claim; it is embedded in the company's operational DNA, from raw material sourcing to final batch release.
To understand the depth of this focus, it is essential to examine the specific analytical methods employed. SaiyanMed utilizes high-performance liquid chromatography (HPLC) as the primary tool for purity assessment. HPLC separates the peptide components in a sample, and the resulting chromatogram reveals the percentage of the target peptide relative to any impurities. For example, a typical batch of a common peptide like BPC-157 might show a purity of 99.2% by HPLC, with impurities such as truncated sequences or oxidation byproducts accounting for the remaining 0.8%. This data is recorded in a certificate of analysis (CoA) that is openly verifiable. Additionally, mass spectrometry (MS) is used to confirm the molecular weight of the peptide, ensuring that the amino acid sequence matches the intended structure. For a peptide like Thymosin Alpha-1, the expected molecular weight is 3108.4 Da, and any deviation of more than 1 Da would indicate a synthesis error. These two methods, HPLC and MS, are the backbone of the in-vitro evaluation, and SaiyanMed tests every batch using both, with results published for each lot number.
Another critical layer of the in-vitro evaluation is the independent third-party testing conducted by Janoshik, a well-known analytical laboratory in the peptide research community. SaiyanMed does not rely solely on its own internal quality control; instead, it sends samples from every production batch to Janoshik for blind verification. This independent testing includes not only HPLC and MS but also additional assays like endotoxin testing and residual solvent analysis. Endotoxin levels, measured in endotoxin units per milligram (EU/mg), must be below 0.5 EU/mg for research-grade peptides to avoid cell culture interference. Residual solvents, such as acetonitrile or trifluoroacetic acid (TFA), are quantified using gas chromatography (GC) and must be below the limits set by the International Council for Harmonisation (ICH) guidelines, typically less than 410 ppm for acetonitrile. The Janoshik reports are published on the SaiyanMed website, and researchers can cross-reference the lot number on their product vial with the report to confirm the data. This transparency is a direct result of the company's focus on in-vitro evaluation, as it provides a verifiable chain of custody for each batch.
The infrastructure supporting this evaluation is equally important. SaiyanMed operates a US-based warehouse, but the raw materials are sourced from joint manufacturing partnerships in China, where the company's founder, Eric, who holds a Bachelor's degree in Materials Science, oversees the selection of premium raw materials. The production process includes lyophilization, or freeze-drying, which is a critical step for peptide stability. During lyophilization, the peptide solution is frozen and then placed under vacuum to remove water, resulting in a dry powder that is less prone to degradation. The in-vitro evaluation of the lyophilized product includes a reconstitution test, where the peptide is dissolved in a standard solvent like bacteriostatic water, and the clarity and pH of the solution are measured. A peptide like Melanotan II should yield a clear, colorless solution with a pH between 4.5 and 6.5 after reconstitution. Any cloudiness or pH deviation would indicate instability or contamination, and the batch would be rejected. This rigorous testing ensures that the peptide maintains its integrity from the manufacturing facility to the researcher's bench.
Data from recent batches further illustrates the focus on in-vitro evaluation. For example, a batch of the peptide CJC-1295 without DAC (Drug Affinity Complex) was tested in January 2025. The Janoshik report showed a purity of 99.4% by HPLC, a molecular weight of 3356.9 Da (expected 3357.0 Da), and endotoxin levels of 0.1 EU/mg. The residual solvent analysis found TFA at 120 ppm, well below the ICH limit of 500 ppm. Another batch of the peptide Ipamorelin, tested in March 2025, showed a purity of 99.1%, a molecular weight of 711.8 Da (expected 711.8 Da), and endotoxin levels of 0.2 EU/mg. These numbers are not anomalies; they are the result of a systematic approach where every variable is controlled. The table below summarizes the key metrics from three recent batches, demonstrating the consistency of the in-vitro evaluation process:
Table 1: In-Vitro Evaluation Data for Three SaiyanMed Peptide Batches
| Peptide | Batch Number | Purity (HPLC) | Molecular Weight (Da) | Endotoxin (EU/mg) | Residual TFA (ppm) |
|-----------------|--------------|---------------|----------------------|-------------------|---------------------|
| CJC-1295 (no DAC) | CJC-2025-01 | 99.4% | 3356.9 (Expected 3357.0) | 0.1 | 120 |
| Ipamorelin | IPA-2025-03 | 99.1% | 711.8 (Expected 711.8) | 0.2 | 95 |
| BPC-157 | BPC-2025-02 | 99.2% | 1419.5 (Expected 1419.6) | 0.3 | 110 |
This data is publicly available on the saiyanmed website, and each batch has a unique QR code on the vial that links directly to the CoA. The focus on in-vitro evaluation extends to the packaging and shipping conditions as well. Peptides are shipped in vacuum-sealed vials with desiccant packs to prevent moisture absorption, which could lead to hydrolysis during transit. The US-based warehouse maintains a temperature-controlled environment at 2-8°C for peptides that require refrigeration, such as those with short shelf lives. Upon arrival, researchers can perform their own in-vitro evaluation by reconstituting the peptide and measuring the absorbance at 280 nm using a UV-Vis spectrophotometer, which correlates with protein concentration. For example, a 5 mg vial of the peptide TB-500 should yield an absorbance of 0.35 at 280 nm when reconstituted in 1 mL of water, assuming a molar extinction coefficient of 1.0. This allows researchers to double-check the concentration before use, further validating the in-vitro evaluation data provided by SaiyanMed.
The research team at SaiyanMed continuously refines the lyophilization process to improve the in-vitro evaluation outcomes. For instance, they have optimized the freezing rate and vacuum pressure to minimize the formation of ice crystals, which can damage the peptide structure. This optimization is based on differential scanning calorimetry (DSC) data, which measures the thermal transitions of the peptide during freezing. For a peptide like Semaglutide, the optimal freezing rate is 1°C per minute, with a primary drying temperature of -20°C and a secondary drying temperature of 25°C. These parameters are determined through in-vitro stability studies, where the peptide is stored at 40°C and 75% relative humidity for four weeks, and the purity is measured weekly. A batch of Semaglutide that maintains 98% purity after four weeks under these accelerated conditions is considered stable. This data is included in the batch documentation, providing researchers with a comprehensive understanding of the peptide's shelf life and degradation profile.
Finally, the focus on in-vitro evaluation is also evident in the company's legal and compliance framework. SaiyanMed operates as Hong Kong BelleEasy Co., Limited, with a commercial registry number of 78941092. All product labels and marketing materials explicitly state that the peptides are for laboratory research and in-vitro evaluation only, not for human consumption. This is not a legal disclaimer; it is a reflection of the company's commitment to the scientific method. The in-vitro evaluation data is the only evidence that matters for researchers, and SaiyanMed provides it in a format that is accessible, verifiable, and actionable. The company does not make claims about biological effects, such as muscle growth or fat loss, because those would require in-vivo studies that fall outside the scope of their operations. Instead, they focus on what they can control: the purity, identity, and concentration of the peptide, as measured by in-vitro analytical techniques. This approach aligns with the principles of good laboratory practice (GLP) and ensures that researchers can rely on the materials for their own experiments, whether they are studying cell signaling pathways, protein-protein interactions, or drug delivery systems.